HC Wainwright Cuts ImmunoPrecise Antibodies (NASDAQ:IPA) Price Target to $5.00

Posted by ABMN Staff on Apr 1st, 2025

ImmunoPrecise Antibodies (NASDAQ:IPA – Free Report) had its target price trimmed by HC Wainwright from $7.00 to $5.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock.

ImmunoPrecise Antibodies Trading Down 4.0 %

Shares of NASDAQ IPA opened at $0.38 on Monday. The company has a current ratio of 1.01, a quick ratio of 0.85 and a debt-to-equity ratio of 0.36. ImmunoPrecise Antibodies has a one year low of $0.27 and a one year high of $1.59. The business has a 50-day moving average price of $0.43 and a two-hundred day moving average price of $0.47. The firm has a market capitalization of $11.69 million, a PE ratio of -0.48 and a beta of 0.09.

ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) last posted its quarterly earnings results on Friday, March 28th. The company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). The business had revenue of $4.23 million during the quarter, compared to analysts’ expectations of $6.59 million. ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 73.74%. As a group, analysts predict that ImmunoPrecise Antibodies will post -0.27 earnings per share for the current fiscal year.

Institutional Trading of ImmunoPrecise Antibodies

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC grew its position in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA – Free Report) by 20.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,558,892 shares of the company’s stock after purchasing an additional 263,451 shares during the period. Ingalls & Snyder LLC owned about 5.41% of ImmunoPrecise Antibodies worth $996,000 at the end of the most recent quarter. Institutional investors and hedge funds own 6.70% of the company’s stock.

ImmunoPrecise Antibodies Company Profile

(Get Free Report)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.